Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Abstract Background Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once weekly tirzepatide is approved in the US and EU for the treatment of type 2...

Full description

Bibliographic Details
Main Authors: Stephen J. Nicholls, Santiago Tofé, Carel W. le Roux, David A. D’Alessio, Russell J. Wiese, Imre Pavo, Katelyn Brown, Govinda J. Weerakkody, Meltem Zeytinoglu, Irene C. Romera
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cardiovascular Diabetology
Subjects:
Metabolic syndrome
Type 2 diabetes
Tirzepatide
Incretin
Online Access:https://doi.org/10.1186/s12933-024-02147-9

Internet

https://doi.org/10.1186/s12933-024-02147-9

Similar Items